Literature DB >> 12270727

Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.

Anita R Schnapp1, Christopher S Eickhoff, Julio Scharfstein, Daniel F Hoft.   

Abstract

Trypanosoma cruzi, the causative agent of Chagas' disease, is an important cause of heart disease in Latin America. The parasite is transmitted mucosally, with both intra- and extracellular life stages in the human host. Cruzipain, the major cysteinyl proteinase of T. cruzi, has been shown to be antigenic in both humans and mice during infection with the parasite. We extend these observations, showing here that multiple murine immune subsets of potential importance for vaccine-induced protection can be induced by cruzipain. Cruzipain-specific serum IgG responses were induced during chronic infection with T. cruzi. In addition, T. cruzi mucosal infection stimulated the development of cruzipain-specific secretory IgA detectable in fecal extracts from infected mice. Cruzipain-specific type 1 cytokine responses characterized by the production of IFN-gamma but not IL-4 were also detectable during murine infection. Furthermore, immunization of mice with a DNA vaccine encoding cruzipain was shown to stimulate cytotoxic T lymphocyte (CTL) responses capable of recognizing and lysing T. cruzi-infected cells. The induction of serum antibody, mucosal IgA, Th1 cytokine and CTL responses by cruzipain in mice supports the use of this parasite protein for further efforts in T. cruzi vaccine development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270727     DOI: 10.1016/s1286-4579(02)01600-3

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  8 in total

1.  Falcipain-1, a Plasmodium falciparum cysteine protease with vaccine potential.

Authors:  Amit Kumar; Krishan Kumar; Reshma Korde; Sunil Kumar Puri; Pawan Malhotra; Virander Singh Chauhan
Journal:  Infect Immun       Date:  2007-01-22       Impact factor: 3.441

2.  Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.

Authors:  Silvia I Cazorla; Pablo D Becker; Fernanda M Frank; Thomas Ebensen; María J Sartori; Ricardo S Corral; Emilio L Malchiodi; Carlos A Guzmán
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

3.  Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.

Authors:  Nicole L Sullivan; Christopher S Eickhoff; Xiuli Zhang; Olivia K Giddings; Thomas E Lane; Daniel F Hoft
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

4.  Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.

Authors:  Matthew H Collins; Julie M Craft; Juan M Bustamante; Rick L Tarleton
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

5.  Repertoire, genealogy and genomic organization of cruzipain and homologous genes in Trypanosoma cruzi, T. cruzi-like and other trypanosome species.

Authors:  Luciana Lima; Paola A Ortiz; Flávia Maia da Silva; João Marcelo P Alves; Myrna G Serrano; Alane P Cortez; Silvia C Alfieri; Gregory A Buck; Marta M G Teixeira
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

Review 6.  Prophylactic and therapeutic DNA vaccines against Chagas disease.

Authors:  Minerva Arce-Fonseca; Martha Rios-Castro; Silvia del Carmen Carrillo-Sánchez; Mariana Martínez-Cruz; Olivia Rodríguez-Morales
Journal:  Parasit Vectors       Date:  2015-02-24       Impact factor: 3.876

7.  DNA Vaccines against Protozoan Parasites: Advances and Challenges.

Authors:  Eric Dumonteil
Journal:  J Biomed Biotechnol       Date:  2007

8.  Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection.

Authors:  María Belén Antonoglou; Andrés Sánchez Alberti; Daniela María Redolfi; Augusto Ernesto Bivona; María Julieta Fernández Lynch; Sofía Noli Truant; María Belén Sarratea; Laura Valeria Iannantuono López; Emilio Luis Malchiodi; Marisa Mariel Fernández
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.